奥美沙坦酯中基因毒性杂质的检测分离及质量新标准研究
[Abstract]:Olmesartan ester is a specific angiotensin II receptor antagonist, which can produce halogenated group of genotoxic impurities in the process of industrial synthesis. In this paper, combined with the industrial production process of raw materials, high performance liquid chromatography (HPLC) was used to detect and isolate these trace genotoxic impurities, and the corresponding separation conditions were explored. A new quality standard for olmesartan ester, which considers the control of genotoxic impurities, has been developed. The main contents are as follows: (1) To establish a method for the detection and separation of brominated genotoxic impurities, C18 column (250 *4.6 mm, 5 micron), mobile phase: 0.1% glacial acetic acid aqueous solution (A): 0.1% glacial acetonitrile solution (B) = 15:85, detection wavelength: 254 nm, flow rate: 1.5 ml @ min-1, column temperature 5-(4', 4'-dibromomethylbiphenyl-2-yl) tetrazole (brominated impurity 1) and N-triphenylmethyl-5-(4', 4'-dibromomethylbiphenyl-2-yl) tetrazole (brominated impurity 2) were separated at 25 C. The specificity, repeatability, quantitative limit and detection limit of brominated impurity 1 and brominated impurity 2 were determined. The relative concentrations of impurities 1 and 2 were well linearized in the range of 0.03-0.25 ug.mL-1. The average recoveries were 94.37% and 94.43% respectively. The relative standard deviations were 2.38% and 2.72% respectively, which ensured the sensitivity and reliability of the method. (2) Establishment of chlorinated genotoxicity. The impurities were detected and separated by Kromasil Eternity 5-Phenyl Hexyl column (250 *4.6 mm); detection wavelength: 215 nm; flow rate: 1.0 ml/min; column temperature: 40 sample volume: 10 ml. mobile phase A: acetonitrile: 2.04 g L-1 potassium dihydrogen phosphate solution (pH 3.4) (20:80); mobile phase B: 2.04 g L-1 potassium dihydrogen phosphate solution (pH 3.4): acetonitrile (20:80); p-4-chloromethyl-5-5-phosphate solution (pH 3.4); Methyl-1,3-dioxacyclopentene-2-one (chlorinated impurity 1) and 4,5-dichloromethyl-1,3-dioxacyclopentene-2-one (chlorinated impurity 2) were validated by a series of methods. The results showed that the relative concentrations of chlorinated impurity 1 and 2 were 0.0003% and 0.0004% respectively, which were lower than the prescribed standard limit (0.0037%). To meet the requirements, product quality can be effectively monitored; (3) Through three batches of product properties, identification, content, inspection and other items of quality research and testing results, the development of new quality standards of olmesartan ester, including related substances, residual solvents used in the process acetone, ethyl acetate, N, N-dimethylacetamide, and other newly established genotoxic impurities Finally, the new quality standards of Omexatane Ester including genotoxic impurities were studied to ensure the quality control of Omexatane Ester in daily production.
【学位授予单位】:浙江工业大学
【学位级别】:硕士
【学位授予年份】:2017
【分类号】:O657.72;TQ463
【相似文献】
相关期刊论文 前8条
1 韩薇薇;吴金龙;;奥美沙坦酯及其关键中间体的合成方法[J];化学试剂;2013年08期
2 徐彩丽,袁华,喻宗沅;奥美沙坦酯的研究进展[J];化学与生物工程;2005年04期
3 胡士现;杨宁;蒋成猛;晏芳;;多条溶出曲线评价奥美沙坦酯片的质量[J];云南化工;2014年03期
4 张海波;陈国俊;孟霆;;奥美沙坦酯合成路线图解[J];中国医药工业杂志;2009年11期
5 李宗品;;中外药企专利战升级[J];中国医院院长;2006年06期
6 张力图,张丽生,郭建霞,黄少珍;茶多酚对饮用塘水基因毒性的抑制作用[J];广西医科大学学报;1997年02期
7 张明;孙二娜;;脱基因毒性乳酸菌的筛选[J];食品研究与开发;2014年13期
8 卢声;;非基因毒性二氨基类直接染料的合成与研究[J];化学世界;2009年08期
相关会议论文 前2条
1 刘红阳;姜一农;;奥美沙坦酯对高糖培养的人系膜细胞保护作用的研究[A];中华医学会第11次心血管病学术会议论文摘要集[C];2009年
2 游碧X ;郭明良;;快得宁农药之致基因毒性机转[A];海峡两岸首届毒理学研讨会论文(摘要)集[C];2001年
相关重要报纸文章 前7条
1 驻京记者 王丹;没有赢家的判决[N];医药经济报;2007年
2 记者 柳志梅;三共制药状告北京万生药业侵权[N];中国医药报;2006年
3 记者 李立;专利大战发生在药品上市前[N];法制日报;2006年
4 陆志城;2002年美国批准上市的新分子实体药物[N];医药经济报;2003年
5 本报记者 白毅;青年英才显锋芒[N];中国医药报;2006年
6 记者 吴辉;“三共”状告“万生”侵权[N];中国知识产权报;2006年
7 雷诺岛;抢仿药“落地”不稳[N];医药经济报;2012年
相关博士学位论文 前1条
1 周迎;心外膜脂肪组织与冠心病进展的相关性研究及其干预治疗[D];中国人民解放军医学院;2016年
相关硕士学位论文 前10条
1 袁抢云;奥美沙坦酯中基因毒性杂质的检测分离及质量新标准研究[D];浙江工业大学;2017年
2 张鸽;抗高血压药物奥美沙坦酯杂质的合成[D];东南大学;2015年
3 李项;奥美沙坦酯合成方法的改进研究[D];北京理工大学;2015年
4 尹茂山;SIRT1/Wnt/β-catenin信号通路在糖尿病心肌病发生发展过程中的变化及奥美沙坦酯的干预作用研究[D];济南大学;2016年
5 许先敏;奥美沙坦酯及其重要中间体规模化生产合成工艺研究[D];浙江工业大学;2017年
6 朱剑波;新工艺合成国产奥美沙坦酯的质量研究[D];湖南师范大学;2013年
7 张世鹏;血管紧张素Ⅱ受体拮抗剂奥美沙坦酯的合成研究[D];沈阳药科大学;2004年
8 郭东华;奥美沙坦酯加氨氯地平与奥美沙坦酯加氢氯噻嗪治疗原发性高血压的疗效观察[D];山西医科大学;2011年
9 李红钊;抗高血压新药奥美沙坦酯的合成研究[D];佳木斯大学;2010年
10 杨艳;奥美沙坦酯对心肌梗死后大鼠缺血心肌组织促血管生成的研究[D];重庆医科大学;2012年
,本文编号:2240350
本文链接:https://www.wllwen.com/kejilunwen/huaxue/2240350.html